{"schema_version":"secwatch.filing_event.v1","accession":"0001723128-25-000059","form_type":"8-K","ticker":"AMRX","cik":"0001723128","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.255745+00:00","generated_at":"2026-05-17T01:23:05.336853+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Amneal Q3 revenue $785M (+12% YoY); GAAP EPS $0.01, adj. EPS $0.17; updated FY guidance","bullets":["Net revenue $785M (+12% YoY); GAAP net income $2M vs loss of $0.2M; diluted EPS $0.01.","Adjusted EBITDA $160M (+1% YoY); adjusted diluted EPS $0.17 (+6% YoY from $0.16).","Specialty +8% driven by CREXONT and UNITHROID; Affordable Medicines +8%; AvKARE +24%.","Incurred $22.5M milestone for XOLAIR biosimilar BLA submission; updated FY2025 guidance.","Launched BREKIYA autoinjector for migraine in October 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001723128-25-000059","json":"https://secwatch.observer/filing/0001723128-25-000059.json","markdown":"https://secwatch.observer/filing/0001723128-25-000059.md","text":"https://secwatch.observer/filing/0001723128-25-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1723128/000172312825000059/0001723128-25-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1723128/000172312825000059/amrx-20251030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:23:05.336853+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}